This study aims to use a clinically validated metagenomic next-generation sequencing (mNGS) assay to provide a demonstration of precision medicine for diagnosis of acute infectious disease in hospitalized patients. From June 2016 to June 2017, 200 patients will be enrolled from multiple hospitals in California and outside of California. Patients will be evaluated to determine the impact on the mNGS assay on diagnostic yield, hospital costs and clinical outcomes.

开始日期2016-06-01

申办/合作机构

The University of California, San Francisco

[+10]

100 项与 DNAnexus, Inc. 相关的临床结果

登录后查看更多信息

0 项与 DNAnexus, Inc. 相关的专利（医药）

登录后查看更多信息

项与 DNAnexus, Inc. 相关的文献（医药）

2023-09-14·Nature

The complete sequence of a human Y chromosome

Article

作者: Olsen, Hugh E ; Wenger, Aaron M ; Haukness, Marina ; Eichler, Evan E ; Murphy, Terence D ; Rhie, Arang ; Chin, Chen-Shan ; Mc Cartney, Ann M ; Cechova, Monika ; Shafin, Kishwar ; O'Neill, Rachel J ; Phillippy, Adam M ; Miga, Karen H ; Thibaud-Nissen, Françoise ; Schatz, Michael C ; McNulty, Brandy M ; Hook, Paul W ; Hunt, Sarah E ; Harris, Robert ; Guarracino, Andrea ; Jain, Miten ; Rautiainen, Mikko ; Medvedev, Paul ; Tomaszkiewicz, Marta ; Nurk, Sergey ; Surapaneni, Likhitha ; Potapova, Tamara ; Gershman, Ariel ; Taravella Oill, Angela M ; Walenz, Brian P ; McDaniel, Jennifer ; Weissensteiner, Matthias H ; Lucas, Julian K ; Shepelev, Valery A ; Asri, Mobin ; Makalowski, Wojciech ; Hansen, Nancy F ; Harvey, William T ; Fungtammasan, Arkarachai ; Markovic, Christopher ; Olson, Nathan D ; Martin, Fergal J ; Diekhans, Mark ; Zook, Justin M ; Formenti, Giulio ; Gerton, Jennifer L ; Hubley, Robert M ; Sedlazeck, Fritz J ; Wilson, Melissa A ; Alexandrov, Ivan A ; Hwang, Stephen ; Ryabov, Fedor ; Hourlier, Thibaut ; Zarate, Samantha ; Makova, Kateryna D ; Grady, Patrick G S ; Sauria, Michael E G ; Haggerty, Leanne ; Paulin, Luis F ; McCoy, Rajiv C ; Kesharwani, Rupesh K ; Bzikadze, Andrey V ; Shumate, Alaina ; Watwood, Allison C ; Altemose, Nicolas ; Garrison, Erik ; Li, Heng ; Koren, Sergey ; Hoyt, Savannah J ; Salzberg, Steven L ; Taylor, Dylan J ; Hartley, Gabrielle A ; Allen, Jamie ; Chen, Nae-Chyun ; Garcia Giron, Carlos ; Halabian, Reza ; Vollger, Mitchell R ; Flicek, Paul ; Porubsky, David ; Storer, Jessica M ; Zhu, Yiming ; Logsdon, Glennis A ; Munson, Katherine M ; Lewis, Alexandra P ; Mikheenko, Alla ; Heinz, Jakob ; Timp, Winston

The human Y chromosome has been notoriously difficult to sequence and assemble because of its complex repeat structure that includes long palindromes, tandem repeats and segmental duplications^1-3. As a result, more than half of the Y chromosome is missing from the GRCh38 reference sequence and it remains the last human chromosome to be finished^4,5. Here, the Telomere-to-Telomere (T2T) consortium presents the complete 62,460,029-base-pair sequence of a human Y chromosome from the HG002 genome (T2T-Y) that corrects multiple errors in GRCh38-Y and adds over 30 million base pairs of sequence to the reference, showing the complete ampliconic structures of gene families TSPY, DAZ and RBMY; 41 additional protein-coding genes, mostly from the TSPY family; and an alternating pattern of human satellite 1 and 3 blocks in the heterochromatic Yq12 region. We have combined T2T-Y with a previous assembly of the CHM13 genome⁴ and mapped available population variation, clinical variants and functional genomics data to produce a complete and comprehensive reference sequence for all 24 human chromosomes.

2023-04-01·OECOLOGIA

Native solitary bee reproductive success depends on early season precipitation and host plant richness

Article

作者: Tobin, Patrick C ; Westreich, Lila R. ; Westreich, Samuel T ; Westreich, Samuel T. ; Tobin, Patrick C. ; Westreich, Lila R

Spring-emerging bees depend upon the synchronized bloom times of angiosperms that provide pollen and nectar for offspring. The emergence of such bees and bloom times are linked to weather but can be phenologically mismatched, which could limit bee developmental success. However, it remains unclear how such phenologically asynchrony could affect spring-emerging pollinators, and especially for those that forage over a relatively short time period. We examined the relationship between weather and host plant selection on the native spring-foraging solitary bee, Osmia lignaria, across 3 years at urban and rural sites in and around Seattle, Washington, USA. We used community science weather data to test the effects of precipitation, wind, and temperature on O. lignaria oviposition and developmental success. We also collected pollen data over two distinct foraging periods, early and late spring, and used Next-Generation Sequencing to identify plant genera from pollen. Among the weather variables, precipitation during the early foraging period adversely affected larval developmental success and adult bee emergence success, but not oviposition. Using DNA metabarcoding, we observed that increases in the number of plant genera in pollen increased adult emergence in both foraging periods, but not oviposition or larval development. We also observed that foraging bees consistently visited certain genera during each foraging period, especially Acer, Salix, and Rubus. However, pollen collected by O. lignaria over different years varied in the number of total genera visited, highlighting the importance of multi-year studies to ascertain bee foraging preferences and its link to developmental success.

2023-01-01·Cell reports

A chromosome-level reference genome and pangenome for barn swallow population genomics

Article

作者: Olivieri, Anna ; Ambrosini, Roberto ; Gallo, Guido R ; Formenti, Giulio ; Stucki, David ; Iannucci, Alessio ; Sozzoni, Marcella ; Saclier, Marielle ; Galati, Elena ; Ferretti, Luca ; Mountcastle, Jacquelyn ; Howe, Kerstin ; Ciofi, Claudio ; Masterson, Patrick ; Lombardo, Gianluca ; Thibaud-Nissen, Françoise ; Haase, Bettina ; Kwak, Woori ; Secomandi, Simona ; Rhie, Arang ; Messina, Graziella ; Torrance, James ; Fungtammasan, Arkarachai ; Caprioli, Manuela ; Jarvis, Erich D ; Ferrer Obiol, Joan ; Abueg, Linelle ; Bonisoli-Alquati, Andrea ; Mousseau, Timothy A ; Møller, Anders P ; Gianfranceschi, Luca ; Balacco, Jennifer ; Rubolini, Diego ; Stanyon, Roscoe ; Torroni, Antonio ; Chow, William ; Fedrigo, Olivier ; Collins, Joanna ; Weber, Kristina

Insights into the evolution of non-model organisms are limited by the lack of reference genomes of high accuracy, completeness, and contiguity. Here, we present a chromosome-level, karyotype-validated reference genome and pangenome for the barn swallow (Hirundo rustica). We complement these resources with a reference-free multialignment of the reference genome with other bird genomes and with the most comprehensive catalog of genetic markers for the barn swallow. We identify potentially conserved and accelerated genes using the multialignment and estimate genome-wide linkage disequilibrium using the catalog. We use the pangenome to infer core and accessory genes and to detect variants using it as a reference. Overall, these resources will foster population genomics studies in the barn swallow, enable detection of candidate genes in comparative genomics studies, and help reduce bias toward a single reference genome.

项与 DNAnexus, Inc. 相关的新闻（医药）

2025-09-15

·EINPresswire

AI in genomics market to reach $9,859.7 million by 2031, registering a CAGR of 40.6%

PORTLAND, DE, UNITED STATES, September 15, 2025 / EINPresswire.com / -- The AI in genomics market refers to the use of artificial intelligence (AI) and machine learning (ML) techniques to analyze and interpret genomic data. Genomics is the study of DNA sequences and how they relate to an organism's traits, diseases, and potential treatments. AI and ML techniques can help scientists and researchers analyze large amounts of genomic data more efficiently and accurately, potentially leading to new discoveries and advancements in personalized medicine. The market for AI in genomics includes companies that provide software, platforms, and services for genomic data analysis, as well as companies that develop AI-powered diagnostics and therapeutics based on genomic data. According to the report, the ๐ ๐ฅ๐จ๐๐๐ฅ ๐๐ ๐ข๐ง ๐ ๐๐ง๐จ๐ฆ๐ข๐๐ฌ ๐ข๐ง๐๐ฎ๐ฌ๐ญ๐ซ๐ฒ ๐ ๐๐ง๐๐ซ๐๐ญ๐๐ $๐๐๐.๐ ๐ฆ๐ข๐ฅ๐ฅ๐ข๐จ๐ง ๐ข๐ง ๐๐๐๐, ๐๐ง๐ ๐ข๐ฌ ๐๐ง๐ญ๐ข๐๐ข๐ฉ๐๐ญ๐๐ ๐ญ๐จ ๐ ๐๐ง๐๐ซ๐๐ญ๐ $๐.๐ ๐๐ข๐ฅ๐ฅ๐ข๐จ๐ง ๐๐ฒ ๐๐๐๐, witnessing a CAGR of 40.6% from 2022 to 2031. ๐๐๐ช๐ฎ๐๐ฌ๐ญ ๐ ๐๐๐ฆ๐ฉ๐ฅ๐ ๐๐จ๐ฉ๐ฒ ๐จ๐ ๐ญ๐ก๐ ๐๐๐ฌ๐๐๐ซ๐๐ก ๐๐๐ฉ๐จ๐ซ๐ญ: https://www.alliedmarketresearch.com/request-sample/11921 ๐๐ก๐ ๐๐ ๐ข๐ง ๐ ๐๐ง๐จ๐ฆ๐ข๐๐ฌ ๐ฆ๐๐ซ๐ค๐๐ญ ๐๐๐ง ๐๐ ๐ฌ๐๐ ๐ฆ๐๐ง๐ญ๐๐ ๐ข๐ง๐ญ๐จ ๐ฏ๐๐ซ๐ข๐จ๐ฎ๐ฌ ๐๐๐ญ๐๐ ๐จ๐ซ๐ข๐๐ฌ, ๐ข๐ง๐๐ฅ๐ฎ๐๐ข๐ง๐ : Genomic Data Analysis: Companies that provide software, platforms, and services for genomic data analysis, including data preprocessing, quality control, alignment, variant calling, and functional annotation. Personalized Medicine: Companies that develop AI-powered diagnostics and therapeutics based on genomic data, including identifying genetic mutations that are associated with specific diseases and developing personalized treatment plans for patients. Drug Discovery and Development: Companies that use AI and ML techniques to accelerate the drug discovery and development process, including identifying drug targets, designing molecules, predicting drug efficacy and toxicity, and optimizing clinical trial design. Clinical Genomics: Companies that provide AI-powered solutions for clinical genomics applications, including genomic diagnostics, prognostics, and therapeutics. Agriculture and Livestock: Companies that use AI and genomics to improve crop yields, develop new crop varieties, and breed healthier livestock. Consumer Genomics: Companies that provide direct-to-consumer genetic testing services, including ancestry testing, disease risk assessment, and lifestyle recommendations. These segments are not mutually exclusive, and some companies may operate across multiple segments in the AI in genomics market. ๐๐จ๐ฏ๐ข๐-๐๐ ๐ฌ๐๐๐ง๐๐ซ๐ข๐จ: The outbreak of the Covid-19 pandemic had a negative impact on the global AI in genomics market, as it disrupted workflows in the healthcare sector around the world during the lockdown. The disease had forced several industries to shut down temporarily, including several sub-domains of the healthcare sector. The pandemic reduced accessibility to the research centers and offices which delayed the development in AI programs. However, AI-driven diagnostics emerged as great solution for quick diagnosis of the disease ๐๐ซ๐จ๐๐ฎ๐ซ๐ ๐๐จ๐ฆ๐ฉ๐ฅ๐๐ญ๐ ๐๐๐ฉ๐จ๐ซ๐ญ (๐๐๐ ๐๐๐ ๐๐ฌ ๐๐๐ ๐ฐ๐ข๐ญ๐ก ๐๐ง๐ฌ๐ข๐ ๐ก๐ญ๐ฌ, ๐๐ก๐๐ซ๐ญ๐ฌ, ๐๐๐๐ฅ๐๐ฌ, ๐๐ง๐ ๐๐ข๐ ๐ฎ๐ซ๐๐ฌ) @ https://www.alliedmarketresearch.com/purchase-enquiry/11921 ๐๐๐ซ๐ ๐๐ซ๐ ๐ญ๐ก๐ ๐ญ๐จ๐ฉ ๐๐ ๐ค๐๐ฒ ๐ฉ๐ฅ๐๐ฒ๐๐ซ๐ฌ ๐ข๐ง ๐ญ๐ก๐ ๐๐ ๐ข๐ง ๐ ๐๐ง๐จ๐ฆ๐ข๐๐ฌ ๐ฆ๐๐ซ๐ค๐๐ญ, ๐๐๐ฌ๐๐ ๐จ๐ง ๐ญ๐ก๐๐ข๐ซ ๐ฆ๐๐ซ๐ค๐๐ญ ๐ฌ๐ก๐๐ซ๐, ๐ซ๐๐ฏ๐๐ง๐ฎ๐, ๐๐ง๐ ๐ข๐ง๐ง๐จ๐ฏ๐๐ญ๐ข๐จ๐ง: Illumina Inc. - A leading genomics company that offers genomic sequencing and array technologies for research, clinical, and applied markets. Qiagen N.V. - A provider of sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research. DNAnexus Inc. - A cloud-based platform for genomic data management, analysis, and collaboration. Freenome Holdings Inc. - A company developing an AI-powered blood test for early cancer detection. Sophia Genetics S.A. - A company offering AI-powered solutions for clinical genomics and precision medicine. Deep Genomics Inc. - A company using AI and genomics to develop new treatments for genetic diseases. Tempus Labs Inc. - A company using AI and machine learning to analyze and interpret clinical and genomic data for precision medicine. Fabric Genomics Inc. - A company providing AI-powered solutions for clinical genomics and drug discovery. Google LLC - A tech giant with various AI-powered genomics initiatives, including the Google Genomics platform and DeepVariant variant calling tool. Amazon Web Services (AWS) - A cloud computing provider that offers various genomic data management and analysis solutions, including the AWS Genomics service. Note that this list is not exhaustive, and there are many other companies and startups operating in the AI in genomics market. ๐๐๐ช๐ฎ๐๐ฌ๐ญ ๐๐ฎ๐ฌ๐ญ๐จ๐ฆ๐ข๐ณ๐๐ญ๐ข๐จ๐ง: https://www.alliedmarketresearch.com/request-for-customization/11921 Based on region, North America held the highest market share in terms of revenue in 2021, accounting for nearly half of the global AI in genomics market, and is likely to dominate the market during the forecast period. This is attributed to a large number of universities and research institutions that are at the forefront of AI research, including Stanford, MIT, Carnegie Mellon University, and the University of California, Berkeley. These institutions attract top talent from around the world and conduct cutting-edge research. Furthermore, The U.S. government and private industry have invested heavily in AI research and development. However, the Asia-Pacific region is expected to witness the fastest CAGR of 46.9% from 2022 to 2031, owing to increase in investments for development of AI and an increase in the number of key players developing AI. ๐๐ซ๐๐ง๐๐ข๐ง๐ ๐๐๐ฉ๐จ๐ซ๐ญ๐ฌ ๐ข๐ง ๐๐๐๐ฅ๐ญ๐ก๐๐๐ซ๐ ๐๐ง๐๐ฎ๐ฌ๐ญ๐ซ๐ฒ Brachytherapy Market https://www.alliedmarketresearch.com/brachytherapy-market-A11122 Plant Tissue Culture Market https://www.alliedmarketresearch.com/plant-tissue-culture-market-A14265 Knee Braces Market https://www.alliedmarketresearch.com/knee-braces-market-A10858 ๐๐๐จ๐ฎ๐ญ ๐๐ฌ: Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of โMarket Research Reportsโ and โBusiness Intelligence Solutions.โ AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain. David Correa Allied Market Research +1 800-792-5285 email us here Visit us on social media: LinkedIn Facebook YouTube X Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

2025-01-27

·生物谷

2025年值得关注的七大生物制药领域趋势：AI驱动、癌症疫苗突破与全球资本热潮

2024年迎来了生物制药行业的显著复苏与创新高潮，这一年中，我们见证了人工智能（AI）在药物开发中的深度应用、癌症疫苗研发的重大进展、基因编辑技术首次获得商业收入等里程碑事件，同时也经历了风险投资市场的回暖以及并购活动的活跃。然而，全球经济的不确定性及政策环境的变化也给行业内企业带来了新的挑战，迫使它们调整策略以适应不断变化的市场环境。那2025年的生物制药行业将会呈现出怎样一幅画卷？近日，德勤健康解决方案中心（Deloitte Center for Health Solutions）对来自美国和亚洲的150名制药、生物技术和生命科学公司的高管进行了调查。结果显示，75%的受访者对未来一年充满信心，他们对公司及整个行业的前景表示乐观。这种积极的态度源于对收入增长的预期（68%的人预计收入将增加）以及科技创新加快所带来的动力。普华永道的分析进一步指出，在经历2024年的相对低迷之后，生命科学领域的并购交易量和价值有望逐步回升。预计这些并购活动将在生物技术、制药和医疗技术领域显著增多，涵盖诊断工具、健康信息系统和医疗设备等多个方面。图片来源：thebluediamondgallery.com 一、AI：超越发现算法的增长 2024年，人工智能（AI）在药物发现和开发领域取得了显著进展。根据德勤的调查，近60%的生物制药高管计划增加对AI的投资，以优化整个价值链。德勤美国生命科学部门负责人Pete Lyons指出，行业正从实验阶段转向实际应用，AI将改变工作方式，但不会减少工作量。随着更多AI技术融入生物制药行业，领先的基于AI的药物开发商预计将获得显著的利润增长。例如，去年11月，Recursion与Exscientia合并，估值高达6.88亿美元；Insilico Medicine则公布了其炎性肠病项目的同行评审细节，并将其管线项目扩展到了31个，其中10个项目已经进入临床阶段。该公司计划推进特发性肺纤维化候选药物ISM001-055进行潜在的关键试验。尽管一些公司选择自主建立AI平台，其他企业则更倾向于通过合作或授权获取先进的AI技术，并将其应用于内部项目中。这种灵活的合作模式促进了知识和技术的快速传播，有助于推动整个行业的进步。在生物制药AI领域的影响下，英伟达（NVIDIA）作为该领域的重要参与者之一，在2024年的市值超过了3万亿美元，并于同年6月实施了10比1的股票分割。进入2025年后，英伟达的新股票价格趋于平稳，截至12月底收盘时仅下跌了0.55%。这一稳定表现反映了投资者对该公司在AI计算能力上的长期看好。二、癌症疫苗：收集后期数据 2025年，癌症疫苗的研发将继续推进，重点关注后期临床数据的收集。莫德纳和默克已启动个体化新抗原疗法（INT）的III期临床试验，分别是Moderna mRNA-4157和Merck V940，旨在评估其在非小细胞肺癌治疗中的效果。莫德纳总裁Stephen Hoge表示，两家公司将继续合作，并计划启动更多项目。这些研究利用Personalis公司的ImmunoID NeXT®平台进行综合肿瘤分析。默克近期投资5000万美元购买了Personalis约16.5%的股权，显示了对这一技术的信心。 BioNTech也在积极扩展其癌症疫苗管线。该公司计划报告其与Regeneron合作的II期临床试验结果，该试验使用西米普利单抗治疗黑色素瘤。此外，BioNTech还将在今年晚些时候或2026年初公布自体基因疫苗cevumeran针对结直肠癌的中期数据，并继续开发基于FixVac平台的HPV16癌症疫苗BNT113。尽管癌症疫苗在过去遇到了挑战，但近年来莫德纳和BioNTech等公司在非随机试验中取得了令人鼓舞的结果。随着更多有意义的数据和成功的积累，研究人员正逐步建立对这项技术的信心，为患者提供更多有效的治疗选择。图片来源：千库网三、金融：风投交易，IPOs反弹 2024年第三季度的数据预示着生物制药初创公司在2025年可能迎来更多的风险投资。根据摩根大通和DealForma的报告，前三季度共完成了319笔风险投资，总额达208亿美元，预计全年融资将达277亿美元。如果这一趋势持续，将扭转过去两年融资金额下降的局面，尽管交易数量有所减少，但每笔投资的规模显著增加。风险投资市场自2021年的440亿美元高点逐渐下滑，至2023年降至235亿美元。然而，2024年出现了“持续看涨”的信号，包括美联储9月降息0.5%，这有望促进第四季度的交易活动。Xaira Therapeutics在ARCH Venture Partners和Foresite Capital领投下获得了超过10亿美元的资金，成为年度最大赢家之一。截至第三季度，已有77家生物制药公司获得1亿美元或以上的投资，超过了2023年的总数。 IPO市场同样表现出色，2024年前九个月共有16家公司上市，筹集了总计30亿美元的资金，远超2023年全年的水平。其中，癌症药物开发商CG Oncology和人工智能医疗公司Tempus分别以4.37亿美元和4.107亿美元的IPO名列前茅。综上所述，2024年的积极迹象为2025年的生物制药行业注入了信心，预示着更大的投资机会和更多的企业上市活动。四、基因编辑：收入、改革和历史 2024年，Vertex Pharmaceuticals与CRISPR Therapeutics合作开发的首个FDA批准的CRISPR疗法Casgevy®实现了200万美元的商业收入，标志着基因编辑疗法迈入商业化阶段。Fyodor Urnov教授等人在《CRISPR Journal》发表文章，强调CRISPR疗法不仅有望带来更多收入，还能为患者提供急需的治疗。Urnov呼吁药物开发者超越单一基因突变的研究，并建议监管机构简化审查流程，支持多导向RNA的应用。他提倡创建“CRISPR治疗中心”，加强学术界和行业的合作，确保更多患者受益于这项技术。除了CRISPR，其他基因编辑技术也在取得进展。Prime Medicine计划在2025年报告其针对慢性肉芽肿病（CGD）的启动编辑疗法PM359的初步临床数据。Wave Life Sciences则将分享其α1抗胰蛋白酶缺乏症（AATD）候选药物WVE-006的Ib/IIa期试验结果，该药物已在人体中成功进行了首次RNA编辑的临床演示。这些进展展示了基因编辑技术的巨大潜力，预示着未来更多的创新疗法将进入临床应用，为多种遗传疾病带来新的治疗希望。五、并购：专利悬崖将会推动中档贸易 2025年，并购活动有望反弹，主要受“专利悬崖”影响。随着重磅药物专利到期，如强生/拜耳的Xarelto®、勃林格殷格翰/礼来的Jardiance®和阿斯利康的Farxiga®，大型生物制药公司急需通过并购补充其产品线。德勤的Pete Lyons指出，这些公司将积极寻找新的增长点。尽管2024年前三个季度的并购活动有所下降，但市场观察人士预计2025年将出现反弹。根据摩根大通和DealForma的数据，2024年前三季度共完成71宗并购，总额为432亿美元，低于2023年的611亿美元。然而，普华永道的Van den Akker认为，2025年规模在50亿至150亿美元之间的中档并购将成为主流，填补大型和小型交易之间的空隙。 Vertex Pharmaceuticals以49亿美元收购Alpine Immune Sciences是2024年最昂贵的交易之一，不仅扩展了Vertex的产品线，还推进了IgA肾病候选药物povetacicept的III期试验。这表明，符合战略逻辑的并购将继续受到青睐。总体来看，生物制药公司的资产负债表依然稳健，行业创新持续进步，预示着2025年并购市场将保持健康活跃的状态。图片来源：arimagenomics.com 六、组学：扩张和整合 2024年，下一代测序（NGS）工具开发商进一步扩展至多组学领域。7月，行业领军企业Illumina收购了单细胞技术开发商Fluent BioSciences，标志着其在多组学领域的布局。Element Biosciences也在2月宣布与DNAnexus合作，使客户能够直接传输AVITI™系统的数据至多组学分析平台。 Singular Genomics推出了G4X™空间测序仪，提供高通量多组学和RNA原位直接测序（Direct-Seq™），并于第三季度交付给早期用户。12月，Singular同意被Deerfield管理公司以每股20美元的价格收购，为其找到了新的发展契机。Illumina CEO Jacob Thaysen博士表示，这些创新正推动公司从基因组学向多组学转型。行业整合趋势明显，Vizgen和Ultivue两家私营公司在10月合并，成为单细胞空间基因组学和多重蛋白质组学分析的领导者。上市公司方面，Bruker在5月以3.926亿美元现金加债务收购了NanoString Technologies，后者曾在三个月前申请破产保护，并涉及与10x Genomics的专利纠纷。尽管如此，10x继续推出新产品和技术改进，如Xenium In Situ单细胞空间成像平台的新功能和Visium空间基因表达平台的高清版，以及Chromium系列的两款新产品，旨在扩大客户群并提升性能。通过这些扩展和整合，领先的公司正逐步实现更少但更大的工具开发商格局，为生物医学研究提供更全面的技术支持。Bruker推出的CellScape™精确空间蛋白质组学平台也体现了这一趋势，满足了高复用免疫荧光的需求。总之，2024年的组学领域见证了显著的技术进步和市场整合，预示着未来更多的创新和发展。七、特朗普归来：在生物制药领域和健康领域的“疯狂” 随着唐纳德·特朗普重返白宫，生物制药和公共卫生行业正准备迎接监管政策的重大变化。特朗普宣布提名Robert F. Kennedy Jr.为卫生与公众服务部部长，与FDA专员Marty Makary博士和NIH主任Jay Bhattacharya共同领导“让美国再次健康”（Make America Healthy Again）议程。Kennedy承诺支持致幻剂的研究与发展，这一消息推动了相关上市公司的股价上涨，投资者期待他能促进精神药物的开发。尽管如此，精神药物领域并非一帆风顺。2024年8月，FDA拒绝了Lykos Therapeutics用于治疗创伤后应激障碍（PTSD）的米多非他明胶囊的新药申请（NDA），要求进行额外的III期试验。尽管这次挫折令人失望，但迷幻疗法研究仍具有巨大潜力，吸引了多个参与者从不同角度探索其疗效和耐受性。这一年中，多家精神药物公司获得了大量投资。Lykos在1月完成1亿美元的A轮融资，Reunion Neuroscience于5月筹集1.03亿美元，Seaport Therapeutics则在10月完成了2.25亿美元的B轮融资，显示了投资者对该领域的持续信心。总体来看，虽然面临挑战，特朗普政府的新政策为生物制药和精神药物研究带来了新的机遇，预示着未来更多的创新和发展。参考文献： Seven Biopharma Trends to Watch in 2025 本文仅用于学术分享，转载请注明出处。若有侵权，请联系微信：bioonSir 删除或修改！点击下方「阅读原文」，前往生物谷官网查询更多生物相关资讯~

疫苗并购临床研究

2024-12-18

·PRNewswire

DNAnexus Recognized by Frost & Sullivan for Ability to Integrate and Synchronize Diverse Clinical and Multi-omics Data

Leading cloud-based enterprise platform for precision health data empowers biopharma companies with actionable insights to accelerate drug discovery and development SAN ANTONIO, Dec. 18, 2024 /PRNewswire/ -- Frost & Sullivan researched the bioinformatics-based drug discovery and development industry, and based on its analysis results, today recognized DNAnexus, provider of the leading enterprise platform for precision health data, with the 2024 Global Enabling Technology Leadership Award in the "bioinformatics-based drug discovery and development industry" category. DNAnexus' cloud-based platform was awarded for its ability to integrate and synchronize clinical, multi-omics, and real-world data, making it accessible, actionable, and secure while unlocking insights that can improve patient lives. The Frost & Sullivan Global Enabling Technology Award recognizes companies that have developed a pioneering technology that enhances current products and enables the development of new products and applications. Industry analysts compare market participants and measure performance through in-depth interviews, analyses, and extensive secondary research to identify best practices in the industry. Today, DNAnexus has more than 45,000 registered users across 48 countries and actively manages more than 105 petabytes of complex clinical genomic, proteomic, and other multi-omic datasets on behalf of a growing network of collaborators. Its comprehensive enterprise platform leverages advanced AI / ML analysis frameworks and meets the most rigorous industry standards for data quality, security, privacy, and regulatory compliance. Frost and Sullivan found the DNAnexus platform offers substantial economic benefits to customers, including a 39% return on investment and a payback period of less than six months. It also significantly reduces operating costs by automating workflows, minimizing compliance risks, and providing continuous, cloud-based updates. "DNAnexus' cloud-based platform eliminates the need to purchase or maintain hardware, and it includes convenient access to a variety of prebuilt tools and workflows," said Surbhi Gupta, Industry Principal, Frost & Sullivan. "The company's trusted research environment concept alleviates data privacy concerns posed by leading healthcare and pharmaceutical organizations. These highly secure and controlled environments allow approved researchers to access, store, and analyze sensitive data remotely." About Frost & Sullivan For six decades, Frost & Sullivan has been world-renowned for its role in helping investors, corporate leaders, and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion. About DNAnexus DNAnexus, the enterprise platform for precision health data, is on a mission to accelerate the development, approval, and delivery of personalized treatments. Building on more than 15 years of bioinformatics innovation and genomics expertise, DNAnexus powers a connected data ecosystem trusted by the world's precision health leaders. This flexible ecosystem makes omics and real-world data accessible, actionable, and secure while unlocking insights that improve patient lives. For more information, visit or follow @DNAnexus on social media. Contact: Lindsey Whitaker E: [email protected] SOURCE Frost & Sullivan WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

100 项与 DNAnexus, Inc. 相关的药物交易

登录后查看更多信息

100 项与 DNAnexus, Inc. 相关的转化医学

登录后查看更多信息